UCB is a global biopharma focused on severe diseases in two therapeutic areas: central nervous system and immunology operations.
The company is listed on the Euronext Brussels Stock Exchange and has its headquarters in Brussels, Belgium. It employs more than 8,500 people in more than 40 countries.
Financial Data
-
31st Dec 19 Source: CRO
- €1.1 million turnover
-
-€0.6 million
profit - 0 employees
-
31st Dec 18 Source: CRO
- €36.9 million turnover
-
€25.8 million
profit - 1 employees
- 11 more years available »
Ranking
By Turnover
(€1.1 million)- 964th in Top Companies
- 96th in Health
- 82nd in Pharma
By Employees
(0)- 1026th in Top Companies
- 94th in Health
- 80th in Pharma
-
- 0
- €1.1 million
Employees
- Steve Turley CEO/Managing Director
Latest News
- 7:10pm Ballymun store was Ikea’s best performer globally when it reopened on May 17th
- 6:36pm Strong earnings and rising oil prices boost European shares to all-time highs
- 5:54pm UK regulator fines pharma firm millions for over pricing of thyroid drug
- 5:54pm UK regulator fines pharma firm millions for over pricing thyroid drug
- 5:15pm US economic growth weaker than expected in second quarter